Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study

Background: The use of immune-modifying biological agents has markedly changed the clinical course and the management of Inflammatory bowel diseases (IBDs). Active post-marketing surveillance programs are fundamental to early recognize expected and unexpected adverse events (AEs), representing a pow...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallarico, Martina, Palleria, Caterina, Ruffolo, Livia, Spagnuolo, Rocco, Naturale, Maria Diana, De Francesco, Adele Emanuela, De Sarro, Caterina, Romeo, Rossella, Citraro, Rita, Doldo, Patrizia, Abenavoli, Ludovico, Gallelli, Luca, Luzza, Francesco, Leo, Antonio, De Sarro, Giovambattista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696291/
https://www.ncbi.nlm.nih.gov/pubmed/36432640
http://dx.doi.org/10.3390/pharmaceutics14112449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696291/
https://www.ncbi.nlm.nih.gov/pubmed/36432640
http://dx.doi.org/10.3390/pharmaceutics14112449

Ejemplares similares